AbbVie braces for impact of Humira biosimilars in Europe
But deal with Samsung prevents US launch until mid-2023
AbbVie hopes risankizumab will rebuild sales after Humira patent expires
Partnership will use novel approach to treating Alzheimer’s.
No-one can launch biosimilars until patent expires next year
First use for Imbruvica outside blood cancer.
Decision paves way for cheaper competitor in autumn 2018.